Loading…
Reported covered position: Senior Health Policy Advisor, Senator Jon Kyl (R-AZ) (2006-2010); Health Policy Advisor, Senator William H. Frist (R-TN) (2003-2006)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services - Modifications to the regulatory framework for clinical diagnostic laboratory tests, including companion diagnostics - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2027 (H.R.8646, S.)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2026 · third_quarter · Q3
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services
Filing targets: Centers For Medicare and Medicaid Services (CMS)
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2026 · second_quarter · Q2
Source: Senate LDA
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Cancer Moonshot
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
- Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
- Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Cancer Moonshot
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
oIssues related to the reauthorization of the FDA drug and device user fee programs oIssues related to data privacy and security oGovernment response to COVID-19, including liability reforms and supply chain issues oDiagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128) oCancer Patient Equity Act of 2021 (H.R. 5377) oBiomarker Testing Coverage Policies Other proposed policies that could affect the coverage, reimbursement, regulation of diagnostic tests or the operations of clinical laboratories.
Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) Issues related to health data privacy and security, including the American Data Privacy and Protection Act (H.R.8152) Issues related to the federal governments COVID-19 response, including liability reforms and supply chain issues
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
oBiomarker Testing Coverage Policies oCancer Patient Equity Act of 2021 (H.R. 5377) Other proposed policies that could affect the coverage, reimbursement, regulation of diagnostic tests or the operations of clinical laboratories.
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
oIssues related to the reauthorization of the FDA drug and device user fee programs oIssues related to data privacy and security oGovernment response to COVID-19, including liability reforms and supply chain issues oDiagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128) oCancer Patient Equity Act of 2021 (H.R. 5377) oBiomarker Testing Coverage Policies Other proposed policies that could affect the coverage, reimbursement, regulation of diagnostic tests or the operations of clinical laboratories.
American Data Privacy and Protection Act
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) Issues related to health data privacy and security, including the American Data Privacy and Protection Act (H.R.8152) Issues related to the federal governments COVID-19 response, including liability reforms and supply chain issues
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
oIssues related to the reauthorization of the FDA drug and device user fee programs oIssues related to data privacy and security oGovernment response to COVID-19, including liability reforms and supply chain issues oDiagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128) oCancer Patient Equity Act of 2021 (H.R. 5377) oBiomarker Testing Coverage Policies Other proposed policies that could affect the coverage, reimbursement, regulation of diagnostic tests or the operations of clinical laboratories.
Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) Issues related to health data privacy and security, including the American Data Privacy and Protection Act (H.R.8152) Issues related to the federal governments COVID-19 response, including liability reforms and supply chain issues
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) Issues related to health data privacy and security, including the American Data Privacy and Protection Act (H.R.8152) Issues related to the federal governments COVID-19 response, including liability reforms and supply chain issues
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S. 2209, H.R. 4128) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs Issues related to data privacy and security
Biomarker Testing Coverage Policies Cancer Patient Equity Act of 2021 (H.R. 5377) Government response to COVID-19, including liability reforms and supply chain issues Issues related to data privacy and security Issues related to the reauthorization of the FDA drug and device user fee programs No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128)
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs
Biomarker Testing Coverage Policies Cancer Patient Equity Act of 2021 (H.R. 5377) Government response to COVID-19, including liability reforms and supply chain issues Issues related to data privacy and security Issues related to the reauthorization of the FDA drug and device user fee programs No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128)
Cancer Patient Equity Act of 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
Biomarker Testing Coverage Policies Cancer Patient Equity Act of 2021 (H.R. 5377) Government response to COVID-19, including liability reforms and supply chain issues Issues related to data privacy and security Issues related to the reauthorization of the FDA drug and device user fee programs No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128)
Federal Employee Student Debt Transparency Act
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
Biomarker Testing Coverage Policies Cancer Patient Equity Act of 2021 (H.R. 5377) Government response to COVID-19, including liability reforms and supply chain issues Issues related to data privacy and security Issues related to the reauthorization of the FDA drug and device user fee programs No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128)
Advancing Tribal Parity on Public Land Act
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
Map Improvement Act of 2019
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S. 2209, H.R. 4128) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs Issues related to data privacy and security
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs
Commercial Fishing and Aquaculture Protection Act of 2019
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S. 2209, H.R. 4128) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs Issues related to data privacy and security
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
Consolidated Appropriations Act, 2021
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
Consumer Protections Against Surprise Medical Bills Act of 2020
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
Consumer Protections Against Surprise Medical Bills Act of 2020
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
Consumer Protections Against Surprise Medical Bills Act of 2020
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
Lower Health Care Costs Act
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
Lower Health Care Costs Act
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
Lower Health Care Costs Act
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
Henrietta Lacks Enhancing Cancer Research Act of 2019
Client: FOUNDATION MEDICINE, INC. · Firm: FOUNDATION MEDICINE, INC.
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services - Modifications to the regulatory framework for clinical diagnostic laboratory tests, including companion diagnostics - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2027 (H.R.8646, S.)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2026 · first_quarter · Q1
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services - Modifications to the regulatory framework for clinical diagnostic laboratory tests, including companion diagnostics
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2025 · fourth_quarter · Q4
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services - Modifications to the regulatory framework for clinical diagnostic laboratory tests, including companion diagnostics - Import of biological specimens for testing in a clinical laboratory
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2025 · third_quarter · Q3
- Medicare coverage and reimbursement of clinical diagnostic laboratory tests, including changes to National Coverage Determination 90.2 issued by the Centers for Medicare and Medicaid Services - Import of biological specimens for testing in a clinical laboratory
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Customs & Border Protection
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2025 · second_quarter · Q2
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2024 · fourth_quarter · Q4
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2024 · third_quarter · Q3
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2024 · second_quarter · Q2
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Filing targets: Food & Drug Administration (FDA), SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2024 · first_quarter · Q1
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2023 · fourth_quarter · Q4
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Cancer Moonshot
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2023 · third_quarter · Q3
- Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2023 · second_quarter · Q2
- Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Cancer Moonshot
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2023 · first_quarter · Q1
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2022 · fourth_quarter · Q4
- Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2022 · third_quarter · Q3
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
- Issues related to data privacy and security - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and theVerifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and LandmarkAdvancements Act of 2022 (S.4348) - Cancer Moonshot
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2022 · second_quarter · Q2
Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) Issues related to health data privacy and security, including the American Data Privacy and Protection Act (H.R.8152) Issues related to the federal governments COVID-19 response, including liability reforms and supply chain issues
Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2022 · first_quarter · Q1
oBiomarker Testing Coverage Policies oCancer Patient Equity Act of 2021 (H.R. 5377) Other proposed policies that could affect the coverage, reimbursement, regulation of diagnostic tests or the operations of clinical laboratories.
oIssues related to the reauthorization of the FDA drug and device user fee programs oIssues related to data privacy and security oGovernment response to COVID-19, including liability reforms and supply chain issues oDiagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128) oCancer Patient Equity Act of 2021 (H.R. 5377) oBiomarker Testing Coverage Policies Other proposed policies that could affect the coverage, reimbursement, regulation of diagnostic tests or the operations of clinical laboratories.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2021 · fourth_quarter · Q4
Biomarker Testing Coverage Policies Cancer Patient Equity Act of 2021 (H.R. 5377) Government response to COVID-19, including liability reforms and supply chain issues Issues related to data privacy and security Issues related to the reauthorization of the FDA drug and device user fee programs No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209, H.R. 4128)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2021 · third_quarter · Q3
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S. 2209, H.R. 4128) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs Issues related to data privacy and security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2021 · second_quarter · Q2
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2021 · first_quarter · Q1
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2020 · fourth_quarter · Q4
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2020 · third_quarter · Q3
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions Cures 2.0 Concept Paper Henrietta Lacks Enhancing Cancer Research Act of 2019 (S. 946) Government response to COVID-19, including liability reforms and supply chain issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2020 · second_quarter · Q2
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2020 · first_quarter · Q1
S.1895, Lower Health Care Costs Act," Section 401, regarding hospital billing practices H.R. 2328, Reauthorizing and Extending Americas Community Health Act, Title IV, regarding hospital billing practices H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, regarding surprise medical billing FDA regulatory policy generally and policy for approval of new oncology diagnostic technologies S.3404/H.R.6102, VALID Act of 2020, all provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION MEDICINE, INC. via FOUNDATION MEDICINE, INC.
2020 · first_quarter · RR
Policies related to regulatory approval and reimbursement for oncology diagnostic technologies.
Policies related to regulatory approval and reimbursement for oncology diagnostic technologies.